Compare Mesoblast Limited (MESO) vs NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) (NWG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) — how do they compare? Mesoblast Limited trades at $14.24 (market cap $1.75B), while NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) trades at $17.13 (market cap $66.98B). The key difference: NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) is far larger — about 38.3× Mesoblast Limited's market cap, and NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) pays a 5.5% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) for 1 Days on average.
| MESO | NWG | |
|---|---|---|
Market Cap | $1.75B | $66.98B |
Volume | 239,027 | 5,259,060 |
Sector | Health | Financials |
52-Week High | $20.96 | $19.42 |
52-Week Low | $13.19 | $13.89 |
Typical Hold Time | 15 Days | 1 Days |
Enterprise Value | $1.83B | $140.55B |
Dividend Yield | — | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares)
NatWest Group is a UK banking company serving personal, business, and institutional customers. Its services include deposits, lending, payments, and wealth management.
Read more on NWG →
